Sector
PharmaceuticalsOpen
₹2,128.25Prev. Close
₹2,135.9Turnover(Lac.)
₹533.28Day's High
₹2,182Day's Low
₹2,099.952 Week's High
₹2,66452 Week's Low
₹1,327.05Book Value
₹160.8Face Value
₹1Mkt Cap (₹ Cr.)
22,503.47P/E
68.38EPS
31.42Divi. Yield
0.41Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 10.46 | 10.46 | 9.51 | 9.51 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,514.79 | 1,281.52 | 1,097.65 | 990.16 |
Net Worth | 1,525.25 | 1,291.98 | 1,107.16 | 999.67 |
Minority Interest |
No Record Found
No Record Found
No Record Found
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Gross Sales | 1,016.94 | 853.17 | 712.93 | 616.94 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 1,016.94 | 853.17 | 712.93 | 616.94 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 37.15 | 37.27 | 23.42 | 13.81 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,819 | 158.19 | 4,36,103.12 | 863.29 | 0.74 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,782.35 | 83.58 | 1,53,540.39 | 518 | 0.52 | 2,302 | 513.62 |
Mankind Pharma Ltd MANKIND | 2,910.6 | 59.91 | 1,20,073.47 | 634.43 | 0 | 2,529.74 | 334.18 |
Cipla Ltd CIPLA | 1,475.75 | 28.16 | 1,19,195.76 | 1,178.16 | 0.88 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,399.45 | 70.36 | 1,15,106.89 | 460 | 0.82 | 2,376 | 222.38 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
SUDHIR JAIRAM VAID
Joint Managing Director & CEO
ANKUR VAID
Non Executive Director
Ravi Kapoor
Nominee
Rajiv Agarwal
Independent Director
BHARTI KHANNA
Independent Director
Amitabh Thakore
Independent Director
Arvind Agarwal
Independent Director
Jayaram Easwaran
Independent Director
Mandayam Chakravarthy Sriraman
Assistant VP (Finance) & CS
S Prakash
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Concord Biotech Ltd
Summary
Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to Concord Biotech Limited dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC.The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat.In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid. In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat.It set up a joint venture in Japan to grow business in 2018.In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in Ind
Read More
The Concord Biotech Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹2151.05 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Concord Biotech Ltd is ₹22503.47 Cr. as of 24 Dec ‘24
The PE and PB ratios of Concord Biotech Ltd is 68.38 and 14.13 as of 24 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Concord Biotech Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Concord Biotech Ltd is ₹1327.05 and ₹2664 as of 24 Dec ‘24
Concord Biotech Ltd's CAGR for 5 Years at N/I%, 3 Years at N/I%, 1 Year at 42.82%, 6 Month at 41.33%, 3 Month at -3.30% and 1 Month at 4.33%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice